Patient and public involvement in research
Messages to professional health researchers
We invited the people we spoke to to give messages to professional researchers about involving people in research. Given that the relationship with researchers sits at the heart of all involvement, these messages feature across the whole site. Here we draw together a few key themes that came up repeatedly. The main message was to encourage professionals to try involving patients and members of the public in their research and discover the different perspectives it can add. Dave X said ‘Each patient is an expert in his own field, on himself and what he’s been through, which is something you as a researcher won’t have. So it’s an on-tap resource. Use us please.’
Patient and public involvement is becoming something researchers are increasingly expected to do; it’s part of how research is conducted and is often necessary for researchers to successfully attract funding for their work. But people wanted to remind researchers that it shouldn’t be seen as a box-ticking exercise if they wanted to get the best out of it and use it to enrich their research. They advised researchers to involve people in the early stages of designing research and engage with them throughout the whole research process. Dave A felt it was also important for researchers to learn from what doesn’t work to improve how they involve people in future.
Patients can probably be involved in all types of research and they will make a positive difference.
Patients can probably be involved in all types of research and they will make a positive difference.
And are there any types of health research where PPI isn’t useful?
There may be, but nothing springs to mind. I would have thought that there would be a role for PPI actually in every possible field. You know, mental health, paediatric care, cardiac care, all of it. Because, almost by definition in all fields of health provision, there will be people who are drawing on that health provision, and they will have a view on how that care is provided. So I can’t really see… Once a patient is involved, or a member of the public is involved, i.e. once your medical research gets out of the laboratory and is actually being administered to patients or members of the public who are patients, then those people will have a voice and should have a voice.
It’s important that patients are included in all cancer trials throughout the UK. But we need to start thinking about what aspects of involvement aren’t working and learning lessons for the future.
It’s important that patients are included in all cancer trials throughout the UK. But we need to start thinking about what aspects of involvement aren’t working and learning lessons for the future.
I think that in the cancer world, we know now, which, which aspects of involvement work. It’s important to have people on the committees, on the national committees, and that, we’ve achieved that. Virtually every committee in the cancer research world has got lay people on it. Where we’ve not got blanket saturation is at the very early stages of thinking about the research process and I have always said that one of my ambitions will be that every portfolio trial within the National Institute of Health Research would have had early input from members of the public. So a lay member on every, at least one, and possibly two lay members on every trial management group for every portfolio trial within the National Institute of Health Research.
I have opportunities, a recent meeting I was at [doctor’s name] lead clinician for the National Institute for Health Research was sitting in the audience, and I looked him in the eye and told him that that was my ambition, and I could see him nodding and smiling. I’m pretty sure that he agrees that that’s important. But how you build the, the groups to ensure that happens, is not simple. I admit it’s not simple, but it’s something that we can work towards and we’re moving towards it all the time.
In the cancer world when I joined the MRC trail there was only a handful of patients sitting on TMGs. There are tens, scores, getting on for hundreds now of TMGs that have got lay people on them. It’s still not blanket.
There are about something like 2,000 national portfolio trials in health research. So that is a big number, probably a quarter of those have had lay input. It needs to be more.
Involve people early on; your research may benefit in unexpected ways.
Involve people early on; your research may benefit in unexpected ways.
A good chair (lay or professional) will encourage everyone to contribute but without pushing them.
A good chair (lay or professional) will encourage everyone to contribute but without pushing them.
Mary said researchers shouldn’t be afraid to involve people. Even though she has a mental health problem, they don’t need to wrap her in cotton wool.
Mary said researchers shouldn’t be afraid to involve people. Even though she has a mental health problem, they don’t need to wrap her in cotton wool.
Margaret advises researchers to make a start with any patients they come across.
Margaret advises researchers to make a start with any patients they come across.
Yes, oh yes. I mean miles ahead of ….
Of other types of illnesses.
…and, well I suppose heart and the rehab are there but certainly within research in Northern Ireland the other clinical networks have not got any PPI. I spoke to about sixteen research nurses before Christmas and said, "How do we start," you know and we just how we started. I said, "All you need is one person," I mean they only need one person, you know, you don't have to have a forum, you just need, you must all know a patient who, you know them well, ask them would they do this. Bring them to a building research partnership day, come together you know and they said, "We'll just go to Margaret," and I said, "No, no, no, no you mustn't say that," you know because the whole NIHR thing is working across, you know, across disease sites.
As opposed to being specific so we're doing quite a lot of work, how we got started in cancer PPI research with the other network for the rest of Northern Ireland, but it's that getting started is the big thing.
Not offering payment excludes some groups of people. But the government needs to address the problem of it affecting their benefits.
Not offering payment excludes some groups of people. But the government needs to address the problem of it affecting their benefits.
So I think it should be offered. It should be offered at a reasonable level to recompense patient’s input. And the question about whether or not that payment interferes with their benefit payments, so that’s another issue that’s important and I wish that the government would sensibly address that. Because it, the, there is some talk that anybody that accepts payment for involvement in, in, public issues of this kind, like cancer research, but other, other types of involvement, would automatically lose entitlement to benefits. That’s, that’s blatantly and obviously wrong. I wish the government would address that sensibly, to make sure that the hard to reach groups have a voice.
Researchers need to put resources in place to support more diverse involvement and think creatively where to find people. Adverts in the Big Issue and using social media might help.
Researchers need to put resources in place to support more diverse involvement and think creatively where to find people. Adverts in the Big Issue and using social media might help.
And again these things sound banal when you say them, but if they don't happen then you don't reach that wider range of people.
Marney receives feedback on how she has made a difference to research.
Marney receives feedback on how she has made a difference to research.
Well only in the sense that I get the document, I look at it, I flag up, typically I would say three to four specific points to address. I usually try and give an overview as to whether I think the project is, you know, is valuable or interesting or, all those sort of things. So there's a broad sense in how's this project been received, so I tend to give that first and then I say these things, I think, could need , usually fleshing out further, you know I may say things like , "It's not clear to me how the psychologist on your team is to be used, are they going to be used to ensure people are able to give consent or to choose appropriate screening tools for their reaction to something?" or you know, so, so that sort of thing, or issues particularly, as I said, issues around if you're going to require the patients to go through all these tests, I think you're going trouble recruiting them. Or, this is going to be, you know, if it's taking medication and coming weekly for blood tests and, you know, having spinal fluid taken and, you know, these sorts of things. I say, "I think you're going to have a significant fall out rate because this is very difficult to live with if you're also dealing with recovery say from a, you know, from an illness." But the level of feedback I get usually says, you know, this is really useful, we're going to incorporate it all or, you know, this is useful and we'll explain further here or yes I see your concerns but actually I'm restricted to a hundred and fifty words and I've already bottled it into a small a space as possible so it's not possible for me to develop it, or …yes so people tend to give me an idea of how they're going to use my information, which of course is important because that informs how I react to the next set of reviewing that I do.
Helen doesn’t know if her involvement has made a difference. If people don’t get feedback on how they’ve contributed they may not feel motivated to continue.
Helen doesn’t know if her involvement has made a difference. If people don’t get feedback on how they’ve contributed they may not feel motivated to continue.
I wouldn't say that it annoys me massively but, I do recognise it from my own research that that is a very, very important part of the process that isn't happening. And I think, actually, that may well be one of the major parts of the process that keeps people participating’ essentially. Participating because you understand what's going on is great, and then being encouraged to participate is great, and then being supported in your participation is great. Enjoying the participation; fantastic. But, you need to understand what it is that you've done with your participation, you need to know. It's not patting somebody on the head but, it's saying "Thank you for what you've done, that was really useful, more of the same would be great, and this is what we have changed in light of all the comments we received." And even [if] it's just generalised, even if it's only something that's been sent round as 'We have received lots of comments, no names mentioned, these were the comments we received and this is what has changed.' I think that is hugely important, yeah.
Researchers need to think about the language they use when presenting information to lay people. They should also provide a lay summary of the study results and acknowledge what lay people have added.
Researchers need to think about the language they use when presenting information to lay people. They should also provide a lay summary of the study results and acknowledge what lay people have added.
We would say, "Would you consider doing a lay summary so that it’s understandable results?" I think it's also important for researchers to acknowledge people who take part in, who actually take part in clinical trials. Simply you know the ovarian group that took part in that big trial sent thank you cards, and we were just looking and discussing that and how important something , we might think very simple, but it's an acknowledgement that people are actually doing something. Now there might be people who never want to know the results of the clinical trial they were in or anything, that might be true, but I think for those who do, I think it's good for researchers to acknowledge that people are saying yes to their trial or their study or whatever they're looking at.
And so you think that as routine there should be a lay summary of the finding sent to participants of research?
Yes or available for participants of research, perhaps not all would want necessarily to have it, but I do, I think that's really important because without those participants the research wouldn't have happened and that, I think, it’s important that there's an understanding of what the results mean.
And I know they have to be published in a certain way and presented at groups. I think it's also very important that researchers acknowledge lay input when they're writing up their research, because they'll name, you know, everybody, the profs this, the doctors that and research assistants, all sorts of people, but I do think it's important that if they've had input from a group or from a person who is a lay person, that they're equally acknowledged and I think that is important.
Research often shows there is a need for more information, but producing a leaflet isn’t enough. People also need verbal information.
Research often shows there is a need for more information, but producing a leaflet isn’t enough. People also need verbal information.
So the leaflet may help with this and leaflets are very good for reference but in my view leaflets are pretty much useless if they're not, if the content is not discussed by a person with the individual. So if someone has a particular condition and there are certain bits of information they need to take on-board, that needs to happen in a conversation and then you say , "Now this leaflet summarises some of what we've talked about and you may want it for reference," but to be valuable it needs contained within it sign-posting to some other source because with time people's needs change so the leaflet will only ever answer somebody's needs for a limited period of time, and if you're lucky, it's the period of time that the patient is in at the point at which they're given the leaflet. But, but that's very often not the case because it's a fairly blunt tool. So they are useful but I think professionals tend to only see the benefits, whereas patients have a much more limited enthusiasm for leaflets, and many are filed but never read and I think quite a few sit around on the table for a few days and then they go in the recycling. So leaflets need handling with care [laughs].
Margaret sees involvement as a way of informing the public that research happens. She’s been involved in events aimed at raising the profile of research.
Margaret sees involvement as a way of informing the public that research happens. She’s been involved in events aimed at raising the profile of research.
We had an education evening to…we invited the general public to, to come and to hear what was happening in the area where I live. And the researchers were more than willing to come and share their research which was amazing stuff. But what was the really important thing was that they were willing to talk in terms and words that we could all understand. And people came in and I think they were just amazed at what is happening because they had no concept of, of the level of research that is going on. They'd heard the word but they had no concept of the level, and really what happened, there were ninety people turned up on that specific night and what had happened is that those people had gone out and told other people about the research that's happening. We also had been publishing newsletters on a quarterly basis, I had to go round different areas, usually with lots of photographs because people look at things with photographs, but just to say some of the things and some of the projects that we're involved in because people like to always see a photograph, like to read it, but what it's doing all the time is saying research is of value, research needs to be done if we're going to improve things for people and that's just an education. So that's the area where we've been involved with and it's specifically in the past few months in raising the profile of research.
Last reviewed July 2017.
Copyright © 2024 University of Oxford. All rights reserved.